Breaking News

Alkermes to Merge With Elan Drug Technologies

Alkermes, Inc. has entered a definitive agreement to merge with Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, for approximately $960 million in cash.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes, Inc. has entered a definitive agreement to merge with Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, for approximately $960 million in cash. The combined companies will be named Alkermes plc. Alkermes plc will have revenue from 25 commercialized products, with future growth expected from products Risperdal Consta, Invega Sustenna, Ampyra, Vivitrol and Bydureon. The combined company is expected to have product, royalty and manufacturing re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters